Patents by Inventor Matthias Will

Matthias Will has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD70+ SOLID TUMOR THERAPY USING GENETICALLY ENGINEERED T CELLS TARGETING CD70
    Publication number: 20230355761
    Abstract: Aspects of the present disclosure relate to compositions comprising a population of genetically engineered T cells that expresses a chimeric antigen receptor (CAR) that binds CD70, and methods of using such for the treatment of CD70+ solid tumors.
    Type: Application
    Filed: November 13, 2020
    Publication date: November 9, 2023
    Applicant: CRISPR THERAPEUTICS AG
    Inventors: Jonathan Alexander TERRETT, Mary-Lee DEQUÉANT, Matthias WILL
  • RENAL CELL CARCINOMA (RCC) THERAPY USING GENETICALLY ENGINEERED T CELLS TARGETING CD70
    Publication number: 20220387572
    Abstract: Aspects of the present disclosure relate to compositions comprising a population of genetically engineered T cells that expresses a chimeric antigen receptor (CAR) that binds CD70, and methods of using such for the treatment of renal cell cancer (RCC).
    Type: Application
    Filed: November 13, 2020
    Publication date: December 8, 2022
    Applicant: CRISPR THERAPEUTICS AG
    Inventors: Jonathan Alexander TERRETT, Mary-Lee DEQUÉANT, Matthias WILL
  • GENETICALLY ENGINEERED IMMUNE CELLS TARGETING CD70 FOR USE IN TREATING HEMATOPOIETIC MALIGNANCIES
    Publication number: 20220387488
    Abstract: Aspects of the present disclosure relate to compositions comprising a population of genetically engineered T cells that expresses a chimeric antigen receptor (CAR) that binds CD70, and methods of using such for the treatment of T cell and B cell malignancies.
    Type: Application
    Filed: May 12, 2022
    Publication date: December 8, 2022
    Inventors: Jonathan Alexander TERRETT, Mary-Lee DEQUÉANT, Matthias WILL
  • THERAPY FOR HEMATOPOIETIC CELL MALIGNANCIES USING GENETICALLY ENGINEERED T CELLS TARGETING CD70
    Publication number: 20220387571
    Abstract: Aspects of the present disclosure relate to compositions comprising a population of genetically engineered T cells that expresses a chimeric antigen receptor (CAR) that binds CD70, and methods of using such for the treatment of T cell and B cell malignancies.
    Type: Application
    Filed: November 13, 2020
    Publication date: December 8, 2022
    Applicant: CRISPR THERAPEUTICS AG
    Inventors: Jonathan Alexander TERRETT, Mary-Lee DEQUÉANT, Matthias WILL
  • GENETICALLY ENGINEERED IMMUNE CELLS TARGETING CD70 FOR USE IN TREATING SOLID TUMORS
    Publication number: 20220378829
    Abstract: A method for treating a solid tumor (e.g., a CD70+ solid tumor) comprising one or more cycles of treatment, each cycle comprising administering to a human patient in need thereof an effective amount of a population of genetically engineered T cells after a lymphodepleting therapy, and optionally a treatment comprising an anti-CD38 antibody. The population of genetically engineered T cells comprises T cells expressing a chimeric antigen receptor (CAR) that binds CD70.
    Type: Application
    Filed: May 12, 2022
    Publication date: December 1, 2022
    Inventors: Jonathan Alexander TERRETT, Mary-Lee DEQUÉANT, Matthias WILL
  • USE OF AN ACTIVATABLE ANTI-PDL1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY IN A COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20220306745
    Abstract: The invention relates generally to use of a combination therapy of an activatable anti-PDL1 antibody and an anti-CTLA-4 antibody for the treatment of cancer.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 29, 2022
    Inventors: Rachel Humphrey, Matthias Will, Yifah Yaron
  • USE OF AN ACTIVATABLE ANTI-PDL1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY IN A NEOADJUVANT COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20220296692
    Abstract: The invention relates generally to use of a neoadjuvant combination therapy of an activatable anti-PDL1 antibody and an anti-CTLA-4 antibody for the treatment of cancer.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 22, 2022
    Inventors: Rachel Humphrey, Matthias Will, Yifah Yaron
  • ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20220162332
    Abstract: The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: September 10, 2021
    Publication date: May 26, 2022
    Inventors: Rachel Humphrey, Lori Carman, Matthias Will, Beiyao Zheng, Kathe Balinski
  • ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220023439
    Abstract: Provided herein are activatable antibodies that when activated specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: November 1, 2019
    Publication date: January 27, 2022
    Inventors: Lori CARMAN, Rachel HUMPHREY, W. Michael KAVANAUGH, Jonathan A. TERRETT, Annie Yang WEAVER, Matthias WILL
  • Activatable anti-PDL1 antibodies, and methods of use thereof
    Patent number: 11168144
    Abstract: The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: November 9, 2021
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Rachel Humphrey, Lori Carman, Matthias Will, Beiyao Zheng, Kathe Balinski
  • ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20210100913
    Abstract: Provided herein are activatable antibodies that specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: July 21, 2020
    Publication date: April 8, 2021
    Inventors: Lori CARMAN, Rachel HUMPHREY, W. Michael KAVANAUGH, Jonathan TERRETT, Annie Yang WEAVER, Matthias WILL
  • ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190117789
    Abstract: Provided herein are activatable antibodies that specifically bind to CD166 and conjugated activatable antibodies that specifically bind to CD166. Also provided are methods of making and using these activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: August 30, 2018
    Publication date: April 25, 2019
    Inventors: LORI CARMAN, RACHEL HUMPHREY, W. MICHAEL KAVANAUGH, JONATHAN TERRETT, ANNIE YANG WEAVER, MATTHIAS WILL
  • ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF
    Publication number: 20190016814
    Abstract: The invention relates generally to activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: May 31, 2018
    Publication date: January 17, 2019
    Applicant: CytomX Therapeutics, Inc.
    Inventors: Rachel Humphrey, Lori Carman, Matthias Will, Beiyao Zheng, Kathe Balinski